Sermorelin, GHRP-6

Sermorelin paired with GHRP-6 delivers sustained GH elevation alongside GHRP-6’s unique appetite-stimulating and cardioprotective properties, making it ideal for bulking phases where caloric surplus is critical for muscle gain. Sermorelin triggers GH production via natural GHRH pathways while GHRP-6 amplifies release and provides appetite enhancement and additional anti-inflammatory benefits promoting rapid tissue repair.

Route

Subcutaneous injection

Dose range

100 mcg – 200 mcg

Frequency

1–3 times per day

Cycle length

8–12 weeks

Not currently stocked by N1 Aminos. Browse what is in stock →

Overview

Sermorelin paired with GHRP-6 delivers sustained GH elevation alongside GHRP-6’s unique appetite-stimulating and cardioprotective properties, making it ideal for bulking phases where caloric surplus is critical for muscle gain. Sermorelin triggers GH production via natural GHRH pathways while GHRP-6 amplifies release and provides appetite enhancement and additional anti-inflammatory benefits promoting rapid tissue repair.

Key advantages include powerful lean mass accumulation, improved appetite for caloric surplus without struggling to eat, enhanced recovery and reduced inflammation, sustained GH elevation, and cardioprotective effects. The appetite boost distinguishes this stack from others, making it ideal for athletes struggling with calories or aging individuals experiencing appetite decline. Applied via daily injection, particularly pre-bed or pre-workout, this combination delivers comprehensive GH benefits alongside practical appetite support.

Studied benefits

  • A powerful blend for those looking to improve appetite and body weight alongside the anti-aging benefits of GH elevation
  • It is particularly effective for improving gastric motility and providing significant improvements in sleep depth

Reported side effects

  • Notable for causing strong appetite stimulation
  • Other potential effects include mild lethargy or water retention

Protocol

Dosing Schedule (Subcutaneous)

Educational reference only. Not medical advice. Research compounds are not approved for human use. Full disclaimer.

TierDose (mcg)Draw at 2.5 mg/mLLog
Standard Research100 mcg Each4 units (0.04 mL)+ Log
Mass/Appetite Study200 mcg Each8 units (0.08 mL)+ Log

Frequency

1–3 times per day.

Timing

30 minutes before a meal if appetite stimulation is the research goal.

Cycle length

8–12 weeks.

Unit calculator

Set your vial and water; the table above updates.

Open the full calculator →
Concentration

2.5 mg/mL

50 doses of 100 mcg per vial

At the starting dose (100 mcg × 7/week for a 8-week cycle) you would use about 5.6 mg, i.e. 2 × 5 mg vials. Higher phases use proportionally more.

Assumes a U-100 insulin syringe (100 units = 1 mL). Educational math only; verify every calculation yourself.

Context

Lifestyle considerations

Follow a high-protein, nutrient-dense diet and be prepared to manage the significant appetite-stimulating effects associated with the ghrelin-mimicking properties of GHRP-6. Use heavy resistance training to leverage the increased caloric intake and elevated GH levels for maximal muscle hypertrophy and recovery. Ensure 7–9 hours of quality sleep to facilitate the deep-recovery processes driven by the dual-action growth hormone axis. Practice precise timing by avoiding all carbohydrate and fat intake for at least 30–60 minutes post-administration to ensure the growth hormone pulse reaches its peak magnitude without metabolic interference.

Evidence

Research summaries

Growth Hormone Releasing Peptide-6 Prevents Doxorubicin-Induced Cardiomyopathy and Protects Multi-Organ Integrity

Findings: Prevents and reverses chemotherapy heart damage, protects liver and kidneys from toxic drug injury, preserves lung function during stress, boosts antioxidant defenses, and improves survival rates in life-threatening conditions.

This 2024 study examined GHRP-6's power to shield hearts from doxorubicin (Dox), a chemotherapy drug that destroys heart muscle as a brutal side effect. Rats on doxorubicin alone developed dilated cardiomyopathy—enlarged, failing hearts—within weeks. But rats receiving GHRP-6 alongside doxorubicin showed almost no heart damage: left ventricular ejection fraction (the heart's pumping power) stayed normal (92.78% vs. saline-treated 20–30%), ventricular dimensions didn't balloon, and heart thickness was preserved. Most strikingly, 84% of GHRP-6-treated rats survived the toxic challenge versus only 42% on placebo—a survival doubling. How? GHRP-6 upregulated the pro-survival gene Bcl-2, suppressed pro-death Bax, reduced oxidative stress (ROS spillover), and enhanced antioxidant enzymes. Beyond the heart, GHRP-6 also protected livers (zero fibrotic scarring), kidneys (prevented tubular damage), and intestines (blocked transmural necrosis). The study concluded GHRP-6 "sustains cellular antioxidant defense" and "preserves cardiomyocyte mitochondrial integrity"—basically, it guards cells' power plants from breaking down. For cancer patients or anyone facing toxin exposure, GHRP-6 represents a breakthrough cytoprotective option with zero serious side effects. Paired with sermorelin, the benefits would likely amplify given sermorelin's pituitary support.

Read the study ↗

EGF + GHRP6 Combined Therapy for Acute Ischemic Stroke: A Phase I/II Clinical Trial

Findings: Restores brain function after stroke, reduces neurological damage and disability, improves survival and walking ability, speeds up recovery with minimal side effects.

This groundbreaking 2024 trial tested GHRP-6 combined with EGF (epidermal growth factor) in acute ischemic stroke patients—a life-or-death condition where brain tissue dies from lack of blood. Thirty-six patients arriving within 12 hours of stroke onset received either standard care (control, n=16) or GHRP-6 + EGF at two dose levels (n=20 total). The treatment groups showed markedly better outcomes: at 90 and 180 days, neurological scores (NIHSS, measuring stroke severity) improved more, walking/daily function (Barthel Index) soared, and disability rating (modified Rankin Scale) shifted toward independence. Critically, survival at 6 months favored the GHRP-6 + EGF groups. The mechanism: GHRP-6 triggers neuroprotection via GHS-R and CD36 receptors, activating survival pathways in brain cells; EGF fuels cell repair and regrowth. The combo targets different nodes of stroke damage simultaneously—inflammation, oxidative stress, apoptosis (cell death), and tissue regeneration—whereas single-drug approaches fail. Safety was excellent: no serious adverse events attributable to the peptides; the study had no safety signals forcing early stopping. This trial proved GHRP-6 safe and effective in humans for neuroprotection, a major clinical breakthrough. When combined with sermorelin, which enhances growth factors and pituitary reserve, the brain's recovery capacity could be further boosted.

Read the study ↗

Pharmacokinetic Study of GHRP-6 in Healthy Volunteers and Direct GHRP-6 Effects on Gut Epithelial Cell Migration

Findings: Boosts gut barrier function and heals intestinal damage from stress or disease, accelerates wound healing throughout the body, protects against multiple organ failure, restores healthy appetite.

This pharmacokinetic study dosed GHRP-6 (100–400 micrograms per kilogram intravenously) to nine healthy male volunteers, mapping how the body absorbs, distributes, and clears this peptide. GHRP-6 was safe, well-tolerated, with a short half-life (~3–5 minutes) and rapid plasma clearance. This short half-life means repeated dosing is necessary (hence three times daily protocols), but it also means no dangerous buildup. Imp

Read the study ↗
More references (5)

Identification

Chemistry

formula
C₁₄₉H₂₄₆N₄₄O₄₂S
molecular weight
3357.9–3357.93 g/mol (free base); 3417.99 g/mol (acetate salt)

Keep exploring

Related peptides

Educational use only. The protocols shown summarise published research and community practice for informational purposes. They are not medical advice, not a prescription, and not a recommendation to use any compound. Research peptides are generally not approved for human use. Consult a licensed clinician. Full disclaimer.
Ask the advisor